Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudine Isaacs

Showing results (11-20 of 329) with videos related to

Pageof 33
Sort By:
Cancer Journal (Sudbury, Mass.)|December 14, 2011
BRCA mutation testing in determining breast cancer therapyKaren Lisa Smith, Claudine Isaacs
The New England Journal of Medicine|October 1, 2015
ClinGen and Genetic TestingBeth N Peshkin, Claudine Isaacs
Journal of the National Cancer Institute|September 20, 2017
Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a FewPaula R Pohlmann, Claudine Isaacs
Breast Disease|October 6, 2007
Management of women at increased risk for hereditary breast cancerKaren Lisa Smith, Claudine Isaacs
Clinical Breast Cancer|July 1, 2010
Prediction of benefit from adjuvant treatment in patients with breast cancerJennifer Eng-Wong, Claudine Isaacs
Nature Clinical Practice. Oncology|August 9, 2006
Does prophylactic surgery reduce the risk of gynecologic cancers arising from the Lynch syndrome?Deepa S Subramaniam, Claudine Isaacs
The Breast Journal|July 12, 2020
Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancerJulie M Collins, Claudine Isaacs
Expert Opinion on Medical Diagnostics|March 19, 2013
Novel molecular prognostic markers in breast cancerTrishna Goswami, Minal Shah, Claudine Isaacs
Cancer|September 26, 2023
Adherence to hormonal therapy after surgery among older women with ductal carcinoma in situ: Implications for breast cancer-related adverse health eventsJean M Mitchell, Thomas DeLeire, Claudine Isaacs
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Neratinib: an option for HER2-positive metastatic breast cancerJoyce A O'Shaughnessy, Ruth O'Regan, Claudine Isaacs
Pageof 33

Showing results (11-20 of 329) with videos related to

Sort By:
Pageof 33
Cancer Journal (Sudbury, Mass.)|December 14, 2011
BRCA mutation testing in determining breast cancer therapyKaren Lisa Smith, Claudine Isaacs
The New England Journal of Medicine|October 1, 2015
ClinGen and Genetic TestingBeth N Peshkin, Claudine Isaacs
Journal of the National Cancer Institute|September 20, 2017
Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a FewPaula R Pohlmann, Claudine Isaacs
Breast Disease|October 6, 2007
Management of women at increased risk for hereditary breast cancerKaren Lisa Smith, Claudine Isaacs
Clinical Breast Cancer|July 1, 2010
Prediction of benefit from adjuvant treatment in patients with breast cancerJennifer Eng-Wong, Claudine Isaacs
Nature Clinical Practice. Oncology|August 9, 2006
Does prophylactic surgery reduce the risk of gynecologic cancers arising from the Lynch syndrome?Deepa S Subramaniam, Claudine Isaacs
The Breast Journal|July 12, 2020
Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancerJulie M Collins, Claudine Isaacs
Expert Opinion on Medical Diagnostics|March 19, 2013
Novel molecular prognostic markers in breast cancerTrishna Goswami, Minal Shah, Claudine Isaacs
Cancer|September 26, 2023
Adherence to hormonal therapy after surgery among older women with ductal carcinoma in situ: Implications for breast cancer-related adverse health eventsJean M Mitchell, Thomas DeLeire, Claudine Isaacs
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Neratinib: an option for HER2-positive metastatic breast cancerJoyce A O'Shaughnessy, Ruth O'Regan, Claudine Isaacs
Pageof 33